Keywords: LANP pp32 ANP32-A Spinocerebellar ataxia type 1 SCA1 Neurite outgrowth Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disease that results from a pathogenic glutamine-repeat expansion in the protein ataxin-1 (ATXN1). Although the functions of ATXN1 are still largely unknown, there is evidence to suggest that ATXN1 plays a role in regulating gene expression, the earliest process known to go awry in SCA1 mouse models. In this study, we show that ATXN1 reduces histone acetylation, a post-translational modification of histones associated with enhanced transcription, and represses histone acetyl transferase-mediated transcription. In addition, we find that depleting the Leucine-rich Acidic Nuclear Protein (LANP)-an ATXN1 binding inhibitor of histone acetylation-reverses aspects of SCA1 neuritic pathology.
Introduction
SCA1 is an autosomal dominant disorder characterized by progressive motor incoordination. Its genetic basis lies in a CAG trinucleotide repeat expansion in the coding region of the ATXN1 gene, that in turn results in a glutamine-repeat expansion in the protein ataxin-1 (ATXN1) (Opal and Zoghbi, 2002; Orr et al., 1993) . As such, SCA1 is similar to eight other polyglutamine expansion diseases, of which Huntington disease is the most common (Orr and Zoghbi, 2007) . As a group these disorders share key features: a delayed onset, a tendency for the glutaminerepeat tract to expand over generations (causing more severe disease and earlier onset), and a relatively circumscribed neuronal degeneration despite widespread expression of the relevant mutant protein. For instance in SCA1, Purkinje cells are the first neurons to be affected. This accounts for motor incoordination or ataxia as the presenting symptom (Orr and Zoghbi, 2007; Wells and Warren, 1998) . With time other neuronal groups degenerate, particularly select neuronal groups in the brainstem. It is from brainstem dysfunction that patients eventually succumb, since they can no longer protect their airway (Orr and Zoghbi, 2007; Wells and Warren, 1998) . There is as yet no treatment to cure this relentless disease; hence the dire need for understanding pathogenic mechanisms so as to inspire avenues for therapy.
It is still unclear which toxic pathways are triggered by mutant ATXN1. However, there are significant clues-particularly those gleaned from key experiments performed using genetically engineered mice. Most illustrative perhaps are the findings that ATXN1 null mice do not display ataxia, whereas ATXN1 transgenic mice and knock-in mice mirror features of the human phenotype, most visibly the ataxia (Burright et al., 1995; Watase et al., 2002) . These results suggest that the incoordination characteristic of SCA1 is for the most part caused by a gain of toxic ATXN1 function. The subsequent observation that mice overexpressing expanded ATXN1 with a mutant nuclear localization signal fail to exhibit neurodegeneration argues for a central role for ATXN1's nuclear properties in pathogenesis (Klement et al., 1998) . One nuclear pathway likely to be involved is transcription, given that ATXN1 regulates transcription in concert with transcriptional modulators, and that mutant ATXN1 causes alterations in gene expression in animal models (Cvetanovic et al., 2007; Lam et al., 2006; Serra et al., 2006; Tsai et al., 2004; Tsuda et al., 2005) . In fact, in mouse models, transcriptional derangements well precede other pathologic and behavioral features of SCA1 (Gatchel et al., 2008; Klement et al., 1998; Lin et al., 2000; Serra et al., 2004) . Recently, we have found that rescuing the levels of at least one gene directly downregulated by expanded ATXN1-the neurotrophic/angiogenic factor VEGF-ameliorates SCA1 toxicity (Cvetanovic et al., 2011) . This result adds further weight to the notion that transcriptional deficits play a role in pathogenesis.
Here we wished to investigate the mechanism by which ATXN1 modulates transcription, particularly focusing on the role of ATXN1 binding corepressors. Specifically, we tested whether modulating the levels of ATXN1-binding corepressor LANP (also known as pp32, ANP32-A), a protein known to inhibit histone acetylation by virtue of a histone masking mechanism (Matilla and Radrizzani, 2005; Opal et al., 2003; Neurobiology of Disease 48 (2012) 526-532 
